Description
Emitasvir Phosphate is an NS5A inhibitor that disrupts the HCV replication complex. The Dongyangguang formulation must be used alongside Sofosbuvir for genotype?1, non?cirrhotic chronic HCV research models . Not intended as monotherapy. While clinically used, these capsules are offered for laboratory and preclinical research in virology, biochemical assays, and pharmacology.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Emitasvir Phosphate Capsules (Dongwei’En) |
| Generic Name | Emitasvir Phosphate |
| Dosage Form | Oral capsule |
| Strength | 100?mg per capsule |
| Pack Size | 28 capsules (0.1?g × 28) |
| Approval Number | H20200015 (NMPA China) |
| Manufacturer | Yichang Dongyangguang Changjiang Pharma Co., Ltd. |
| Storage Conditions | Store ??30?°C, sealed |
| Intended Use | Laboratory research: HCV NS5A inhibition, antiviral synergy, resistance studies |
Mechanism of Action
Emitasvir Phosphate targets the HCV NS5A protein, blocking viral replication by disrupting the formation of the replication complex. Used in tandem with Sofosbuvir, it enhances antiviral efficacy against genotype 1 HCV
Research Applications
Genotype 1 HCV replication and inhibition assays
Antiviral combination therapy studies (e.g., with Sofosbuvir)
Resistance profiling against NS5A inhibitors
Pharmacokinetic and pharmacodynamics research in hepatic cells
Safety & Handling
For research use only—not for clinical or veterinary use
Handle with PPE in lab environments
Store as directed and discard if capsules degrade
Core Keywords
Emitasvir Phosphate capsules, DongweiEn NS5A inhibitor, HCV genotype 1 research drug, NMPA H20200015, sofosbuvir combination study, hepatitis C antiviral capsules
Research Use Disclaimer
This product is strictly for laboratory and preclinical research use. It is not approved for diagnostic, clinical, therapeutic, or veterinary use. Misuse may result in health or regulatory consequences. Use only under qualified protocols and institutional guidance.


Reviews
There are no reviews yet.